bpc 157 human clinical trial gastric ulcer BPC-157 and the gut–brain axis: emerging links between cytoprotection and neuroregeneration Stable Gastric Pentadecapeptide BPC 157
Description
Some studies also show protective effects
Die Substanz wirkt damit auf einer hnlichen pharmakologischen Achse wie L-Arginin oder die klinisch eingesetzten NO-Donatoren, aber mit einem regenerations-spezifischen Profil
Reusing a needle dulls the tip, causing more pain and tissue damage, and poses a serious risk of bacterial contamination and infection
Presently, BPC 157 therapy has still limited but encouraging clinical evidence (no toxicity in clinical trials (i.e., effective in ulcerative colitis, phase II) and toxicology studies without lethal dose (LD1)), and much more should be further achieved [1,2,3,4,5,6,7,8,9,10,11]
No regulatory body has approved any GLP-1 medication for this condition
Sterile water should only be used if the entire vial will be consumed within 24 hours
